Abstract Several naturally occurring phytohormones have shown enormous potential in the prevention and treatment of variety of different type of cancers. Strigolactones (SLs) are a novel class of plant hormones produced in roots and regulate new above ground shoot branching, by inhibiting self-renewal of undifferentiated meristem cells. Here, we study the effects of six synthetic SL analogs on breast cancer cell lines growth and survival. We show that SL analogs are able to inhibit proliferation and induce apoptosis of breast cancer cells but to a much lesser extent ''non-cancer'' lines. Given the therapeutic problem of cancer recurrence which is hypothesized to be due to drug resistant cancer stem cells, we also tested the ability of SL analogs to inhibit the growth of mammosphere cultures that are typically enriched with cancer stem-like cells. We show that SLs are potent inhibitors of self-renewal and survival of breast cancer cell lines grown as mammospheres and even a short exposure leads to irreversible effects on mammosphere dissociation and cell death. Immunoblot analysis revealed that SLs analogs induce activation of the stress response mediated by both P38 and JNK1/2 MAPK modules and inhibits PI3K/AKT activation. Taken together this study indicates that SLs may be promising anticancer agents whose activities may be achieved through modulation of stress and survival signaling pathways.
Introduction
Breast cancer continues to be the major cause of cancerrelated deaths in North American women and other western countries, with an estimated 1.38 million new cancer cases diagnosed worldwide [1] . While there has been a small decline in breast cancer-related deaths in the past decade, it continues to be the leading cause of cancer-related death in women.
An established history exists for plant-derived compounds as effective anticancer agents [2] . Approximately, 25% of drugs used in the last 20 years are derived directly from plants. Vincristine, irinotecan, taxanes, and camptothecins are all examples of plant-derived anticancer compounds. More recently, a number of phytohormones have been assessed for their ability to inhibit the growth and survival of human cancer cell lines. Cytokinins are important phytohormones that regulate plant cell division and exhibit different inhibitory activities toward cancer cells [3] [4] [5] [6] . Methyl jasmonate (MJ) is a ubiquitous plant stress hormone belonging to the jasmonate family. MJ has been reported by numerous groups to induce apoptosis in cell lines derived from various cancer types including breast, prostate, lung, and bladder cancer [7] . MJ's mechanism of action involves disruption of hexokinase function, resulting in severe ATP depletion and mitochondrial perturbation. The cytotoxic effects of MJ are dependent of glucose availability and involve modulation of AKT activation and generation of ROS [8] [9] [10] . Brassinosteroids (BRs) are plant steroids which regulate a number of plant processes including growth, differentiation, senescence, and disease resistance. BRs have been isolated from seeds, fruits, leaves, galls, and pollen. In cancer cell lines, BRs regulate cyclin D1 and cyclin-E levels causing G1 arrest and apoptosis [11, 12] .
Strigolactones (SLs) are a novel class of phytohormones, so named because they contain lactone groups and were first identified as inducers of seed germination of the root parasitic plant, Striga spp. [13] . SLs exert positive and negative regulation as they promote branching of the symbiotic arbuscular mycorrhizal (AM) fungi [14] , regulate development of root meristems [15] and inhibit shoot branching by controlling axillary meristem cells growth [16] [17] [18] . Meristem cells are undifferentiated stem cells which can produce lateral organs in response to endogenous and environmental cues, while simultaneously maintaining a central pool of pluripotent stem cells [19] . Interestingly, it was shown that SLs cause meristem cell cycle arrest and atrophy mainly by inhibiting cyclin B transcription ( [20] and unpublished data). Currently, more than 10 natural SLs exist and a number of synthetic analogs have been synthesized and used in various studies [21] [22] [23] . Here, we sought to examine whether SL analogs have an inhibitory effect on human breast cancer cells, and cancer stem-like cells growth and survival. We show for the first time that SL analogs can inhibit cancer cell proliferation and induce apoptosis (in the low micromolar range). We show that SL analogs are potent inhibitors of mammosphere formation and cancer stem-like cell survival. In addition, SL analogs inhibited hormone responsive and hormone independent breast cancer cell lines. Immunoblot analysis revealed that SL analogs activated the stressinduced MAPKs, P38, and JNK1/2 and inhibited PDK1 and AKT. Taken together, this study indicates that SLs may be promising anticancer agents whose mechanism of action may involve stress and survival signaling modulation.
Methods

Cell culture
Cells were grown at 37°C in a humidified 5% CO 2 -95% air atmosphere. MCF-7, T47D, MDA-MB-231, MDA-436, and BJ fibroblasts (ATCC, Manassas) were maintained in DMEM supplemented with 10% fetal bovine serum (FBS). MCF-10A were maintained in DMEM supplemented with 5% horse serum (Atlanta Biologicals), 20 ng/ml epidermal growth factor (EGF) (Sigma), 10 lg/ml insulin (Sigma), and 500 ng/ml hydrocortisone (Sigma).
Mammosphere growth
Adherent cells were gently trypsinized (0.05% trypsin/ EDTA) washed 29 in PBS and filtered through a 40 lM cell sieve to obtain a single cell suspension. MCF7 cells were diluted to a concentration of 10,000 cell/ml in serumfree phenol red-free MEBM (MEGM Bulletkit, Lonza) supplemented with 5 lg/ml bovine insulin, 20 ng/ml recombinant EGF, 20 ng/ml basic fibroblast growth factor (Gibco), 19 B27 supplement, 0.5 lg/ml hydrocortisone as previously described [24] . For MDA-MB-231 mammosphere cultures serum-free phenol red-free CnT-27 medium with growth additives (CellnTEC Advanced cell systems, Bern, Switzerland) was used as previously described [25] . 0.1 ml was seeded per well of a ultralow attachment 96-well plates. The following day the indicated doses of GR-24 (parts per million, ppm) or vehicle alone (0.6% acetone f/c) were added. Media was replenished every 3-4 days. Self-renewal capacity of the mammospheres was determined by re-plating and producing further generations of mammospheres. Secondary mammospheres were cultivated by dissociation (trpsinization with gently vortexing) of 10-14-day-old primary mammospheres. Single cell suspensions were obtained as described above.
Strigolactone treatments SL analogs were solubilized in acetone (Sigma) at stock concentrations of 1666.67 (GR24, MEB55, ST362, EGO9C) and 7,500 ppm (EGO5, ST357). Cells were treated at the indicated doses by diluting the hormone to the required highest concentration in the appropriate culture medium.
Crystal violet growth assays Cells were seeded at 1,500 (MDA-MB-231, MDA-MB-436, and BJ fibroblasts) or 4,000 cells per well of 96-well plates. The following day media was replaced with phenol-free DMEM supplemented with 10% charcoal-stripped FBS and the indicated doses of GR24, SL analogs or vehicle (acetone) alone as control. At the indicated time points, individual plates were fixed and stained with crystal violet solution (0.5% crystal violet and 25% methanol) for 15 min, washed several times in distilled water and plates air dried overnight. Sodium citrate solution (0.1 M) was used to solubilize bound crystal violet and optimal densities were measured at 560 nm (Glomax Ò -Multi Detection plate reader, Promega).
XTT viability assay
Cells were seeded into a 96-well plates at 1,500 cells per well (MCF10, MDA-MB-231, MDA-MB-436) or 4,000 cells (MCF-7) per well in triplicate in normal growing media. The following day media was replaced with phenol-free DMEM supplemented with 10% charcoal-stripped FBS and the indicated final concentrations of SL analog or vehicle (acetone) alone. Cells were incubated for 3 days, at which time XTT (2,3,-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)-carbonyl]-2H-tetrazolium inner salt) reduction was used to quantify viability according to manufacturer's instruction (ATCC). Cells were incubated with XTT reagent for 2-3 h at 37°C in a humidified 5% CO 2 -95% air atmosphere. Absorbance was recorded by a photometer SPEKTRAFluor Plus (Tecan, Salzburg, Austria) at 450 nm with 750 nm of reference wavelength. Cell survival was estimated from the equation: % cell survival = 100 9 (At -Ac), where At and Ac are the absorbencies (450 nm) of the XTT colorimetric reaction (ATCC) in treated and control cultures, respectively, minus non-specific absorption measured at 750 nm. Absorbance of medium alone was also deducted from specific readings.
Cell cycle analysis DNA content was assessed by flow cytometry. Cells were seeded at densities of 1.5 9 10 5 cells (MDA-MB-231, MDA-MB-436) or 4 9 10 5 cells (MCF-7) per well in six-well plate culture dishes. The following day, the media was replaced with phenol-free DMEM supplemented with 10% charcoal-stripped FBS with the indicated concentrations of SL analogs or vehicle alone (acetone). After 48 h, cells were washed twice with 19 PBS (pH 7.4), centrifuged at 360g for 10 min at 4°C, and fixed in chilled ethanol (70%; v/v in PBS) with gentle vortex mixing. To determine their DNA contents, the cells were stained with 40 lg/ml propidium iodide (PI) and analyzed using a FACSCalibur flow cytometer and analyzed using CellQuest analysis software (Becton-Dickinson, San Jose, CA).
Aldeflour expression MCF-7 mammospheres were trypsinized, gently vortexed and passed through a 40 lM cell filter to produce single cell suspensions. Cells (5 9 10 5 ) were washed and resuspended in growth media (Lonza). To identify the Aldefluor-stained cell population with ALDH1 enzymatic activity, the Aldefluor kit (Stem Cell Technologies), which is designed for optimal identification and isolation of stem cells through specific interaction with human ALDH1 was used. Briefly, cells were suspended in Aldefluor assay buffer containing uncharged ALDH1-substrate, BODIPY-aminoacetaldehyde (BAAA), and incubated for 45 min at 37°C, with gently vortexing every 15 min. BAAA is taken up by living cells through passive diffusion and then converted by intracellular ALDH into a negatively charged reaction product BODIPY-aminoacetate, which is retained inside cells expressing high levels of ALDH1, causing the cells to become brightly fluorescent. Fluorescent ALDH1-expressing cells were detected in the green fluorescence channel (520-540 nm) of a FACScan instrument (BD Biosciences). A set of cells were stained using the identical conditions with the specific ALDH inhibitor, diethylaminobenzaldehyde (DEAB), to serve as a negative control for the experiment. PI (Sigma) fluorescence was detected using the orange fluorescence channel. Cells incubated with BAAA and DEAB were used to establish the baseline fluorescence of cells and ALDH1-positive fraction. Data were analyzed by using Cell Quest software (BD Biosciences).
Immunoblotting
Cell lysates were prepared using a lysis buffer containing 50 mM Tris-HCl (pH 7.5), 125 mM NaCl, 0.5% NP-40, 0.1% SDS, 0.25% sodium deoxycholate, 1 mM EDTA, 50 mM NaF, 1 mM sodium orthovanadate, 2.5 mM sodium pyrophosphate, 1 mM sodium b-glycerophosphate, 1 mM PMSF, and a protease inhibitor cocktail (Roche Molecular Biochemicals) and cleared by centrifugation. Protein concentration was determined using the BCA Protein Assay (Pierce), and 20-50 lg of lysate were separated in a 10 or 12% SDS-PAGE gel. After wet transfer, membranes were blocked for 30 min at room temperature in 5% BSA (Sigma) in Tris-buffered saline containing 0.1% Tween-20. Primary antibody was incubated for either 1.5 h at room temperature or overnight at 4°C. Secondary antibody was incubated for 45 min at room temperature, and proteins were visualized with West Pico Stable (Pierce). All antibodies were used at 1:1,000 dilution unless otherwise stated. pT308AKT, AKT, pT180/Y182 P38MAPK, P38MAPK, pT202/Y204 ERK1/2, ERK1, pT183/Y185 pJNK1/2, pT71ATF2, pT581 MSK1, pT334 MAPKAPK, pS82 HSP27 (Cell Signaling Technology, Danvers, MA), a-tubulin (Biomarkers, 1:50,000), and horseradish peroxidase-conjugated anti-rabbit IgG and antimouse IgG (1:5,000, Pierce).
Statistical analyses
Results are presented as average ± SD of replicate analyses and are either representative of, or inclusive of at least two independent experiments. Statistical analyses were performed using Student's t test (two-tailed, paired) versus vehicle controls and regarded as being significant when p \ 0.05 (*). Higher powers are significant (p \ 0.01, p \ 0.001) and also employed and indicated in each figure legend. IC 50 doses for SLs were calculated by interpolation of the sigmoidal dose-response curves (Graphpad Prism 4.0 software). Briefly, linear regression was performed between relevant y-axis data points and interpolation calculated for x-axis unknowns.
Results
GR-24 inhibits the growth of human breast cancer cell lines
The effect of GR-24 ( Supplementary Fig. S1 ) on long-term cancer cell line growth was assessed by crystal violet assay. MCF-7 (estrogen receptor positive (ER?), tumorigenic, non-metastatic), MDA-MB-231, MDA-MB-436 (ER negative (-), metastatic), and BJ fibroblasts (normal, non-neoplastic line) were treated with GR-24 at a dose range of 0.5-10 ppm (1.65-33 lM). Growth was monitored for up to 10 days. Concentrations of 2.5-5 ppm of GR-24 resulted in a significant reduction in growth compared to vehicle-treated controls in MCF-7, MDA-MB-231, and MDA-MB-436. BJ fibroblasts showed no significant reduction in growth over this time period (Fig. 1a) . A small reduction was observed at the highest concentration (10 ppm), however, this was minor when compared to the growth inhibition achieved by the same concentration of GR-24 in MCF7 and MDA-MB-231 cells. To determine the concentration of GR-24 at which 50% of long-term proliferation was inhibited (IC 50 ) after 7 days, optical densities at day 7 were plotted as a percentage of vehicle controls (Fig. 1b) (Fig. 1b) .
GR-24 induces G2/M arrest and apoptosis
To investigate the effect of GR-24 on cell cycle progression, DNA content analyses were carried out by PI staining using flow cytometry. MCF-7, MDA-MB-231, and MDA-MB-436 cells were treated with 10, 5, and 0.5 ppm concentrations of GR-24 for 48 h and the non-tumorigenic breast cell line MCF10A was used as a control. GR-24 treatment causes a dose-dependent increase in the percentage of cells in G2/M phase and a concomitant decrease in the percentage of cells in G1 phase in all tumorigenic cell lines but no change was observed in the cell cycle distribution of MCF10A cells upon GR-24 treatment (Fig. 2) . At higher concentrations (10 ppm), GR-24 caused an increase in the sub-G1/apoptotic fraction of MDA-MB-231 (4.6-fold) and MDA-MB-436 cells (3.4-fold) compared to vehicle controls, indicating increased apoptosis. MCF-7 cells showed no change in the subG1 fraction at 10 ppm (Fig. 2) .
GR-24 inhibits the growth and reduces viability of breast cancer stem-like cell enriched mammosphere cultures Tumor initiating cells (TICs) or cancer stem cells (CSCs) are intrinsically resistant to conventional chemo-and radiation therapies [26] . These cells are able to regenerate the cellular components of the original tumor eradicated by such treatments, and ultimately lead to recurrence. The ability to target this cell population is important to develop effective treatment regimes. Mammosphere culture has been used widely for the enrichment of breast CSCs. MCF-7 cells can be propagated as ''mammospheres'' under non-adherent, serum-free growing conditions [27, 28] . To determine if GR-24 could inhibit MCF-7 mammosphere formation, MCF-7 cells were grown as mammospheres in the presence or absence of GR-24 (Fig. 3a) . Mammosphere formation was completely inhibited in the presence of 2.5-5 ppm of GR-24, and severely attenuated at 1 ppm (p \ 0.01), 5-fold below the concentration required to inhibit monolayer growth ( Fig. 1) . At 0.5 ppm concentrations, growth was inhibited to a lesser degree, however, mammospheres were often smaller (\50 lM) than vehicle-treated controls (p \ 0.05). Similar results were obtained when secondary MCF-7 mammospheres were grown in the presence of GR-24 ( Fig. 3b) . To assess the generality in mammosphere growth inhibition by GR-24, another breast cancer cells line, MDA-MB-231, was tested (Fig. 3c) . At 5 ppm, GR-24 completely blocked MDA-MB-231 mammosphere formation. At 2.5 ppm, mammopheres growth was severely attenuated, with mammospheres being substantially smaller (\50 lM) compared to vehicle control groups. Importantly, the concentrations of GR-24 necessary to block MCF-7 and MDA-MB-231 mammosphere formation were 5.7-and 2.7-fold lower, respectively, than the IC 50 doses for monolayer growth. Mammospheres therefore exhibit a greater sensitivity to the growth inhibitory effects of GR-24 versus monolayer culture. This is an interesting finding since mammosphere cultures reportedly are enriched with TICs and those have been shown to be inherently resistant to chemotherapy [26, 29] .
Effect of GR-24 on mammosphere viability and stem cells marker expression Mammosphere viability was assessed by XTT assay (ATCC). At 5 ppm, GR-24 reduced viability by approximately 80% (98.4% ± 3.4 to 16.4% ± 4.6) (Fig. 4a) . Interestingly at 2.5 ppm where mammosphere formation is completely inhibited, viability remains at 68.6% ± 12.4, suggesting that apoptotic cell death cannot account solely for inhibition of mammosphere formation at this concentration. To further investigate GR-24 induced inhibition of mammosphere formation, the expression of breast stem cells markers were examined.
Aldehyde dehydrogenase (ALDH1) has been shown to be a functional marker in the isolation of TICs in many cancer types [30, 31] and MCF-7 TICs can be selected on the basis of their ALDH activity in combination with other surface markers [32] . ALDH activity was enriched in primary mammospheres relative to adherent culture and secondary mammosphere culture reached further enrichment (Fig. 4b) . GR-24 treatment of primary mammospheres reduced ALDH activity from 6 to 2%. This data suggests that GR-24 is a potent inhibitor of mammosphere formation and down regulation of ALDH by GR-24 may account for this activity.
Strigolactone analogs are effective growth inhibitors of breast cancer cell lines An additional five synthetic SL analogs were obtained ( Supplementary Fig. S1 ) and tested for their ability to inhibit the growth of MCF-7 and MDA-MB-231 cells. MCF-10A cells were included as an example of a nontumorigenic line. XTT viability assays were carried out in the presence of the indicated doses of SLs following 3 days of treatment. Resulting differences in absorbance readings following SL treatment reflect changes in proliferation and cell survival (Fig. 5) . IC 50 concentrations are indicated (Table 1) To assess SLs stability in aqueous solution, each SL was diluted to the desired concentration in media and stored at 4°C for 3 days, at which time the SL containing media was overlayed onto cells. After 3 days growth and viability was assessed (XTT) and results compared to cells treated with freshly diluted SLs (Supplementary Fig. S2 ). All SLs retained similar levels of activity over this time period, with the exception of EG5 which completely failed to inhibit MCF-7 growth. For this reason, all SLs were diluted fresh from acetone stocks into media to desired concentrations and overlayed onto cells within 1 h. Where necessary, media was refreshed every 3 days.
Strigolactone analogs inhibit cell cycle progression and induce apoptosis
Here, we previously showed that GR-24 treatment caused an increase in the percentage of MCF-7 and MDA-MB-231 cells in G2/M phase and apoptosis in MDA-MB-231 and MDA-MB-436 cells. To determine whether these additional SL analogs also induced a similar mechanism of growth inhibition, cell cycle analysis was carried out. Results show a dose-dependent increase in the percentage of MDA-231 and MCF7 cells in G2/M phase (Fig. 6) . At concentrations 25% above the IC 50 /72 h, there was evidence of increased apoptosis in MDA-MB-231 cells with increased percentages of cells in the subG1 fraction. MCF-7 cells were less sensitive to the effects of SLs at the doses tested. BJ fibroblasts were not sensitive to the effects of SLs at the doses tests (Table 2) . Hoechst staining was used to analyze changes in the nucleus. ST362 treatment at 5-10 ppm resulted in increased nuclear condensation and fragmentation changes indicative of apoptosis (Fig. 7a) . To determine if continual SL exposure is required for growth inhibition and reduced cell survival, MDA-MB-231 cells Fig. 5 Effect of strigolactone analogs on human cancer cell line growth and viability. Cells were seeded into 96-well plates in normal growing media. The following day media was replaced with phenol-free DMEM supplemented with 10% charcoal-stripped serum and the indicated doses of strigolactone analog or vehicle (control) alone. Viability was assayed after 3 days (XTT, ATCC). Graphs are representative of two independent experiments with duplicate replicate wells for each analysis were treated with either ST362 or MEB55 at 5 and 10 ppm for 2, 4, and 24 h. At each time point, the SL was removed and media replaced with fresh growth media. After a total of 24 h an XTT assay was carried out (Fig. 7b) . A significant decrease in viability was induced as early as 4 h of SL treatment (p \ 0.01). No changes in cell viability were observed after 2 h exposure. Continual exposure (24 h) to each SL induced a greater reduction in cell viability (p \ 0.001) compared to 4 h exposure. These results indicate that SL analogs induce non-reversible and timedependent decreases in cell viability.
MCF-7 mammosphere growth is inhibited by strigolactone treatment
Given the similar effects the other SL analogs had on breast cancer cell line growth compared to GR-24, we anticipated that the SLs would also have similar effects on MCF-7 primary mammosphere formation. As expected, all five SLs were able to completely block mammosphere formation at concentrations of 5 ppm and above (Fig. 8a, b ). ST362 and MEB55 were also able to block mammosphere growth at 2.5 ppm. ST357 showed a significant reduction in mammosphere growth at 2.5 ppm (p \ 0.01). ST357, ST362, and MEB55 also significantly inhibited mammosphere formation at 1 ppm (p \ 0.01). This data is consistent with these SLs being the most potent inhibitors of MCF-7 monolayer growth (Fig. 5 , Table 1 ). Like GR-24, the doses required to inhibit mammosphere formation were lower than that required to inhibit proliferation in monolayer cultures (5-fold lower; ST362 and MEB55, 3-fold lower; ST357). XTT viability assays were carried out and reduced viability correlated with increased concentration of SLs (Fig. 8c) . To determine if the sensitivity to SLs treatments was specific to mammosphere formation or whether it extended to the integrity and survival of mature mammospheres, MCF-7 mammospheres were grown in the absence of SLs and after 7 days (or once mammospheres had reached a mean diameter of over 100 lM), SLs were added to the growth media (Fig. 9) at the indicated doses. Mammospheres were monitored visually after 24 and 48 h. No changes were observed following 24 h of SLs treatment (data not shown). After 48 h, mammospheres treated with ST362, ST357 and MEB55, at doses of 5 and 2.5 ppm, exhibited a looser morphology and appeared to be dissociating. Representative images of mammospheres treated with 5 ppm concentrations are shown (Fig. 9a) . Mammospheres treated with EGO9C showed a less dramatic morphological change, which correlates with the reduced potency of this SL to inhibit mammosphere formation (Fig. 8) . Following 5 days of treatment, mammosphere numbers (C100 lM) were counted and data presented as percentage of vehicle-treated control (Fig. 9b) . At 5 ppm concentrations, EGO5, EGO9C, ST357, ST362, and MEBB55 reduced mammosphere numbers from 86.7 ± 6.8 (vehicle control) to 23 ± 5, 38 ± 6.2, 6 ± 2, 8.3 ± 3.5, and 9.3 ± 1.5%, respectively. At 2.5 ppm concentrations, mammosphere numbers were reduced to 35 ± 6.9 (EGO5), 52 ± 12.3 (EGO9C), 22 ± 8.5 (ST357), 6 ± 1.7(ST362), and 20.7 ± 8.6 (MEB55). As expected, these results correlate closely with the analogs ability to inhibit mammosphere formation (Fig. 8) . XTT viability assays were also carried out on dissociated mammospheres.
Strigolactone analogs activate stress-activated MAPKs and inhibit survival signaling
To investigate the signaling mechanisms elicited by SLs in cancer cells, MDA-MB-231 cells were treated with SL analogs for 1, 4, or 8 h and lysates were analyzed by immunoblotting. The superfamily of MAPK enzymes plays a pivotal role in cell growth, survival, and cellular stress responses. The best characterized MAPKs fall into three families, the mitogen-activated extracellular signal-regulated kinases (ERK1/2) which are activated in response to positive proliferation signals, c-Jun amino (N)-terminal kinases (JNK1/2/3) and p38 isoforms (p38a, b, c, d), both are activated by environmental stress stimuli such as DNA damage, UV irradiation, and inflammatory cytokines. There was no change in the total protein levels of ERK1/2 ( Fig. 10a) although some dose-independent changes were noted in pERK1/2. Interestingly, ST362 induced a timedependent and dose-dependent increase in pP38 levels which was first evident after 4 h of SL exposure. At 4 and 8 h, pP38 levels increased 5-and 13-fold, respectively, following ST362 treatment compared to vehicle controls (Fig. 10b) . To determine if pP38 levels translated into activation of down-steam signaling, nuclear P38 substrates, activating transcription factor 2 (ATF2), which belongs to the ATF/cAMP response element-binding (CREB) protein family of basic region leucine zipper proteins, MSK1 (mitogen-and stress-activated protein kinase), and heat shock protein 27, HSP27, were analyzed [33, 34] . Phosphorylation of ATF2 and HSP27 was induced in response to ST362 (Fig. 10a, c, e ). Levels were markedly increased between 4 and 8 h after ST362 treatment and therefore followed a similar time course of activation as pP38 MAPK (Fig. 10a) . There was no change in pMSK1 indicating that either p38 signaling is uncoupled from MSK1 activation or MDA-MB-231 cells already have a high basal level of pMSK1. Importantly, pT581 MSK is also a target of ERK1/2, whose phosphorylation was unchanged following SL treatment [35] . Another SL analog, MEB55 was also able to induce phosphorylation of p38 and ATF2 after 4 h (Fig. 10d, f) . Significant cross talk exists between P38 and JNK1/2 and both modules share subsets of MAPKKKs [36] . Treatment with MEB55 also resulted in increased pJNK1/2 after 4 h (Fig. 10d) . To determine if P38 was directly responsible for the SL-induced phosphorylation of ATF2 and HSP27, cells were treated with a pharmacological P38 inhibitor, SB203580. SB203580 function was confirmed by immunoblotting for pT334 MAPKAPK, a direct P38 target [37] . pT334 MAPKAPK phosphorylation was decreased in a dose-dependent manner following SB203580 exposure (Fig. 10f) . pT334 MAPKAPK was not increased upon MEB55 treatment, like pMSK1 (Fig. 10a, f) , indicating that SLs treatment induces activation of only specific subset of P38 targets. Treatment of cells with SB203580 at concentrations of 2 and 10 lM was sufficient to inhibit HSP27 phosphorylation (Fig. 10e) induced by ST362 but even (Fig. 10f) and instead resulted in a dose-independent increase in pATF2 levels. pP38 MAPK levels were also increased in SB203580-treated cells, a phenomenon also reported on the reagent datasheet (Cell Signaling Technology, Danvers, MA). These results show that P38 is not responsible for ATF2 phosphorylation in this system. ATF2 can also be phosphorylated on T69 and T71 directly by JNK1/2 and by Ras-ERK1/2 pathway [38] . Since ERK1/2 activation did not change upon SL exposure (Fig. 10a ), JNK1/2 seems the likely candidate. The PI3K/AKT pathway regulates a wide range of cellular functions including survival and proliferation [39] . AKT activation requires phosphorylation of two critical residues, S473 near the carboxyl terminus which is considered a requirement for subsequent T308 phosphorylation and maximal AKT activation [40, 41] . pT308 AKT levels decreased dramatically between 4 and 8 h in cells treated with MEB55 and remained low at 24 h (Fig. 11 ). Cells treated with the less potent SL analog, EGO9C, displayed a slight delay in the inhibition of AKT phosphorylation, occurring between 8 and 24 h. GSK3a/b activity is inhibited by phophorylation on S9 [42] . pS9/21GSK3a/b did not correlate closely with pAKT, however, decreased pGSK3a/ b was observed after 24 h (Fig. 11) . PDK1 phosphorylates AKT on T308 [40] , which is itself activated by phosphorylation on S241 [43] . Levels of pS241 PDK1 were reduced upon SL treatment and correlated closely with reduced AKT phosphorylation observed in SL treated cells (Fig. 11 ).
Discussion
Here, we have presented data showing that the synthetic SL, GR24, and several SL analogs possess inhibitory effects toward breast cancer cell lines growth and survival. All six analogs induced a G2/M arrest with varying degrees of apoptosis in breast cancer cells lines. Non-tumor ''normal'' lines (MCF10A and BJ fibroblasts) displayed only limited growth inhibition and only at the highest dose ranges tested, suggesting that tumorigenic cells are more sensitive to the growth inhibitory effects of SLs and that SLs induce different responses in cancer and normal cells. Furthermore, SL inhibitory effects were not limited to breast cancer cells and colon, lung and prostate cancer cells also exhibit increased sensitivity to growth inhibition effects of SL analogs (data not shown). ST362 and MEB55 induced a non-reversible reduction in cell viability after only 4 h which correlated with phosphorylation of p38 MAPK, JNK1/2 and inhibition of AKT. p38 and JNK1/2 are stress-activated MAPKs which play a crucial role in stress signaling cascade and are associated with cell cycle arrest [44] and apoptosis in some cell systems [45, 46] . p38 MAPK has been reported to bind to and activate p53 and cause p53-induced apoptosis [47] . Although, SL analogs were able to induce apoptosis in cells expressing both wildtype (MCF-7) and mutant p53 (MDA-MB-231,MDA-MB-436, T47D), MCF7 cells were less sensitive. Further experiments utilizing specific inhibitors are required to determine whether SL-induced apoptosis and cell cycle arrest is dependent on p38 or JNK1/2 activation. While HSP27 phosphorylation was blocked by p38 pharmacological inhibitor, it did not block the increase in ATF2 phosphorylation, which also could be activated by JNK1/2. The differential response of cells to SL analogs (cytostatic versus cytotoxic) was dose dependent but may also SLs reduced mammosphere growth and induced mammosphere dissociation which correlated with their ability to decrease viability. The similar effects of SLs analogs toward plant stem cells [17, 18] may indicate universal mechanisms of action.
In conclusion, this is the first study to assess the effects of SLs, a novel class of phytohormones, on mammalian cells and particularly cancer cells. This study demonstrates that SLs may represent a new class of anticancer therapeutic, able to target the bulk tumor and also are effective at targeting ''cancer stem-like cells.'' The mechanism of action may involve stress signaling activation and inhibition of survival signaling through inhibition of AKT. 
